For the quarter ending 2025-06-30.
| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| Revenues | 0 | |||
| Revenues-Clinical Trial Supply | 0 | |||
| Research and development | 68,000 | |||
| General and administrative | 1,249,000 | |||
| Total operating expenses | 1,317,000 | |||
| Operating loss | -1,317,000 | |||
| Other income, net | 2,000 | |||
| Interest income | 2,000 | |||
| Foreign exchange losses | -3,000 | |||
| Gain on deconsolidation of subsidiary | 0 | |||
| Total other income (expense), net | 1,000 | |||
| Loss before taxes | -1,316,000 | |||
| Income tax benefit | 2,000 | |||
| Net loss | -1,318,000 | |||
| Dividend on convertible exchangeable preferred shares | 20,000 | |||
| Net loss applicable to common shareholders | -1,338,000 | |||
| Basic EPS | -0.98 | |||
| Diluted EPS | -0.98 | |||
Cyclacel Pharmaceuticals, Inc. (CYCCP)
Cyclacel Pharmaceuticals, Inc. (CYCCP)